Related Experiment Videos
MMP-mediated events in diabetes.
M E Ryan1, N S Ramamurthy, T Sorsa
1School of Dental Medicine, Department of Oral Biology and Pathology, State University of New York at Stony Brook 11794-8702, USA. mryan1@hotmail.com
Annals of the New York Academy of Sciences
|July 23, 1999
Summary
Chemically modified tetracyclines (CMTs) show promise in managing diabetes complications like periodontitis and nephropathy. These compounds, unlike traditional antibiotics, may offer therapeutic benefits for long-term diabetes care.
Area of Science:
- Biomedical Science
- Pharmacology
- Endocrinology
Background:
- Diabetes mellitus (DM), both Type I and Type II, is linked to aggressive periodontitis.
- Understanding the systemic/local interaction mechanisms is crucial for effective treatment.
Purpose of the Study:
- Investigate mechanisms of diabetes and periodontitis interaction.
- Evaluate novel pharmacologic approaches using chemically modified tetracyclines (CMTs).
Main Methods:
- Utilized rat models for Type I and Type II DM.
- Conducted in vitro and in vivo experiments to assess CMTs' efficacy.
- CMTs were evaluated for matrix metalloproteinase (MMP) inhibitory properties and effects on diabetes complications.
Main Results:
- CMTs demonstrated superior MMP inhibition compared to doxycycline in vitro, with CMT-5 showing unique non-reactivity with zinc.
- In vivo studies confirmed CMTs and doxycycline inhibited MMP activity, enzyme expression, and alveolar bone loss.
- CMT-8 treatment significantly reduced cataracts, proteinuria, and tooth loss in Type II DM rats, with minimal effects from doxycycline.
Conclusions:
- CMTs, distinct from antibiotic tetracyclines, exhibit therapeutic potential for managing long-term diabetes complications.
- CMT treatment improved survival rates in Type II diabetic rats, suggesting broader therapeutic applications.